In contrast, 10-year DFS was not significantly influenced by age or menopausal status in BRCA1/BRCA2 mutation carriers, but patients with ER-positive tumors had worsened DFS (with a similar non-significant trend for DSS), compared with patients with ER-negative BC (Supplementary Figure S4). This evidence concerns the gene BRCA2 and breast cancer.